Abstract:American Journal of HematologyVolume 98, Issue 5 p. E106-E109 CORRESPONDENCEFree Access Ruxolitinib combined with dexamethasone in adult patients with newly diagnosed Hemophagocytic lymphohistiocytosis: A single-center pilot trial De Zhou, De Zhou orcid.org/0000-0002-3698-2750 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXianbo Huang, Xianbo Huang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorMixue Xie, Mixue Xie Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorLixia Zhu, Lixia Zhu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXin Huang, Xin Huang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXueying Li, Xueying Li orcid.org/0000-0002-9609-1984 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXiudi Yang, Xiudi Yang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorLi Li, Li Li Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJingjing Zhu, Jingjing Zhu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXiaolong Zheng, Xiaolong Zheng Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJianai Sun, Jianai Sun Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorShuqi Zhao, Shuqi Zhao Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorWenjuan Yu, Wenjuan Yu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorWanzhuo Xie, Wanzhuo Xie orcid.org/0000-0002-0966-5581 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorHongyan Tong, Hongyan Tong orcid.org/0000-0001-5603-4160 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJie Jin, Corresponding Author Jie Jin [email protected] orcid.org/0000-0002-8166-9915 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this authorHonghu Zhu, Corresponding Author Honghu Zhu [email protected] orcid.org/0000-0003-2343-0436 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this authorXiujin Ye, Corresponding Author Xiujin Ye [email protected] orcid.org/0000-0002-4553-2751 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], zhuhhd[email protected], [email protected]Search for more papers by this author De Zhou, De Zhou orcid.org/0000-0002-3698-2750 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXianbo Huang, Xianbo Huang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorMixue Xie, Mixue Xie Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorLixia Zhu, Lixia Zhu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXin Huang, Xin Huang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXueying Li, Xueying Li orcid.org/0000-0002-9609-1984 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXiudi Yang, Xiudi Yang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorLi Li, Li Li Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJingjing Zhu, Jingjing Zhu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXiaolong Zheng, Xiaolong Zheng Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJianai Sun, Jianai Sun Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorShuqi Zhao, Shuqi Zhao Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorWenjuan Yu, Wenjuan Yu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorWanzhuo Xie, Wanzhuo Xie orcid.org/0000-0002-0966-5581 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorHongyan Tong, Hongyan Tong orcid.org/0000-0001-5603-4160 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJie Jin, Corresponding Author Jie Jin [email protected] orcid.org/0000-0002-8166-9915 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this authorHonghu Zhu, Corresponding Author Honghu Zhu [email protected] orcid.org/0000-0003-2343-0436 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this authorXiujin Ye, Corresponding Author Xiujin Ye [email protected] orcid.org/0000-0002-4553-2751 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this author First published: 15 February 2023 https://doi.org/10.1002/ajh.26877 De Zhou, Xianbo Huang and Mixue Xie contributed equally to the work. AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL To the Editor: Hemophagocytic lymphohistiocytosis (HLH) is a rapidly progressive and life-threatening disease that can be classified into primary and secondary HLH, most adult patients have secondary HLH, and the main secondary causes are infection, rheumatic disease, and malignancy. The current first-line treatment regimen such as HLH-94 or HLH-2004 are largely extrapolated from pediatric HLH; however, the prognosis of adult HLH is worse than that of children.1, 2 In addition to its unsatisfactory efficacy, the toxicity of HLH-94/HLH-2004 regimens has resulted in relatively high treatment-related mortality,2 Therefore, more efficient and less toxic induction therapy is needed in secondary HLH. Excessive production of cytokines contributes to the pathogenesis of HLH. Recent studies have indicated that ruxolitinib, a small-molecule inhibitor of Janus kinases (JAKs), which are essential for cytokine signaling, may be therapeutic in HLH. A prospective study demonstrated that ruxolitinib is effective and safe in adults with secondary HLH,3 and all patients responded to ruxolitinib and survived for more than two months. Moreover, Lauren K. Meyer et al.4 demonstrated that hypercytokinemia of HLH reduces the apoptotic potential of CD8+ T cells, leading to relative dexamethasone resistance, and this apoptotic potential is restored both in vitro and in vivo upon exposure to ruxolitinib. Based on the above studies, we performed this single-center, pilot study to evaluate the efficacy and tolerability of Ru-D in adult patients with secondary HLH at the First Affiliated Hospital, College of Medicine, Zhejiang University. Patients enrolled in this study met the following criteria: (1) fulfilled at least five of the eight HLH-2004 criteria for HLH; (2) male or female, older than 18 years; (3) no prior chemotherapy treatment for HLH; and (4) signed an informed consent form before participating in the study. Patients who met any one of the following were ineligible: central nervous system involvement, presence of a malignancy, HIV infection, and pregnant women. Patients in this study underwent an 8-week period of treatment. The Ru-D regimen consists of ruxolitinib (15 mg twice daily for 8 weeks) and dexamethasone (initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering). For follow-up and salvage treatment, we employed the following criteria: (1) If patients did not respond to the Ru-D regimen after 7 days or relapsed at any point during treatment, they entered a rescue regimen such as HLH-94 or doxorubicin-etoposide-methylprednisolone (DEP); (2) If patients were diagnosed with lymphoma after enrollment, chemotherapy was immediately started; (3) After 8 weeks of treatment, if no recurrence and no HLH-related gene mutations were detected, treatment was discontinued, and these patients entered the follow-up stage; (4) Allo-HSCT was performed in patients who met the criteria for allo-HSCT. The primary endpoint was the overall response during treatment with the Ru-D regimen in this study. The overall response rate (ORR) included the percentage of patients with a complete response (CR), a partial response (PR), or an improvement in the measures of HLH. Efficacy was evaluated 7, 14, 28, and 56 days after initiating Ru-D therapy. The efficacy of treatment was assessed according to the evaluation criteria proposed by Franco et al5 Secondary endpoints were safety and tolerability, progression-free survival (PFS), overall survival (OS), and changes in biomarkers between baseline and post-treatment. Adverse events in this study were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (CTCAE 5.0). From April 1, 2021 to May 31, 2021, a total of 8 patients were enrolled in this study. The main clinical characteristics of the patients enrolled are summarized in Table 1. All the patients were adults, and the median age was 48 years (range 23–77 years). Among the 8 patients, five were eventually diagnosed with lymphoma-associated HLH (LAHS) after enrollment. The remaining three included one bacterial infection-associated HLH and two cases of Epstein–Barr virus-associated HLH (EVB-HLH). Serum EBV-DNA copies were positive in seven patients (102–106 copies/mL) and were negative in the patient who was diagnosed with bacterial infection-associated HLH. The eight patients had ECOG performance status scores of 2 to 4, and most patients were steady at 3 or 4. TABLE 1. Baseline characteristics and response of enrolled patients. Clinical features Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Age(years) 37 39 54 69 76 77 42 23 Gender Female Male Male Female Female Female Female Male ECOG score 2 4 3 3 3 3 2 4 Previous therapies IVIG, antibiotics, antivirals, corticosteroid IVIG, antibiotics, corticosteroid Antibiotics, antivirals, corticosteroid Antibiotics, corticosteroid Antibiotics Antibiotics Antibiotics, corticosteroid Antibiotics, corticosteroid Etiology NKTCL Bacterial infections DLBCL PTCL EBV-HLH PTCL EBV-HLH NKTCL Fever Yes Yes Yes Yes Yes Yes Yes Yes Splenomegaly Yes No Yes Yes No No Yes Yes Absolute neutrophil count (×109/L) 1.3 12.07 4.76 0.8 1.7 0.5 0.9 0.6 Hemoglobin concentration (g/L) 77 113 121 82 89 124 81 92 Absolute platelet count (×109/L) 32 282 81 89 67 23 31 3 Triglyceride concentration (mmol/L) 3.14 1.94 2.03 1.06 1.25 3.38 2.31 4.43 Fibrinogen concentration (g/L) 1.05 3.67 6.78 0.96 1.48 1.8 0.5 1.28 Ferritin concentration (μg/L) 1151.8 19176.6 4222.6 2299.4 32847.2 20241.4 5156.3 >40 000 Hemophagocytosis in bone marrow Yes Yes No No Yes Yes Yes Yes Natural killer cell activity (%) 21.05 6.95 14.84 — — — 16.44 14.48 Natural killer cell CD107a (%) 10.44 0.99 3.49 — — — 4.56 1.52 Soluble CD25 (pg/mL) 58 240 20 917 78 770 — — — 13 437 43 403 HLH-2004 criteria 7/8 6/8 5/8 5/8a 5/8a 5/8a 7/8 8/8 EBV-DNA (copies/mL) 3.29 × 106 Negative 9.20 × 102 2.58 × 103 1.23 × 103 9.34 × 102 3.31 × 103 9.47 × 106 Treatment days 26 56 14 52 56 20 56 2 Best Response PR CR Improvement in measures of HLH CR CR PR CR NR Duration of Response (days) 26 269 141 52 244 20 234 — Survival No Yes No No Yes No Yes No Survival time (days) 175 450 141 332 425 20 415 2 Reason for death Progression of lymphoma — CRPA infection Relapse of lymphoma — Bronchiectasis with massive hemoptysis — Progression of HLH Note: Normal reference range: Ferritin concentration < 500 μg/L, Triglyceride concentration 1.70 < mmol/L, Fibrinogen concentration 2.0 ~ 4.0 g/L, soluble CD25 ≤ 6400 pg/mL, soluble CD163 88 ~ 902 pg/mL, Natural killer cell activity≥15.11%, Natural killer cell CD107a ≥ 10%. Abbreviations: CR, complete response; CRPA, carbapenem-resistant pseudomonas aeruginosa; DLBCL, diffuse large B-cell lymphoma; EBV, Epstein–Barr virus; ECOG, Eastern Cooperative Oncology Group; IVIG, intravenous immunoglobulin; NKTCL, NK/T-cell lymphoma; NR, no response; PTCL, peripheral T-cell lymphoma. a Natural killer cell activity and Soluble CD25 were not tested. Patients were followed up until June 30, 2022 or until death, with none lost to follow-up. Table 1 also shows the response outcomes in detail. The median follow-up time was 8.5 (range, 0.1–15.0) months. The ORR to the Ru-D regime was 87.5% (7/8), with 50% (4/8) showing CR, 25.0% (2/8) PR, and 12.5% (1/8) improvement in measures of HLH, 12.5% (1/8) no response (NR). Among the LAHS patients, one patient (20%) achieved CR, two patients (40%) achieved PR, and 1 patient (20%) achieved improvement in measures of HLH, and 1 patient (20%) NR. All the 3 non-LAHS patients achieved CR, and no recurrence has occurred so far. The OS was 75% (6/8) at 2 months, 50% (4/8) at 6 months and 37.5% at 12 months. Although the overall mortality rate was 62.5% (5/8), there was only one death directly related to HLH. The Ru-D treatment in our study was well tolerated, with no toxicities leading to dose reduction or discontinuation of treatment observed. Ruxolitinib has been reported to have a risk of hematological toxicity, which is difficult to evaluate because cytopenia is also the major clinical feature of HLH. We found that only 1 patient (12.5%) had grade III anemia during Ru-D therapy. Four additional patients (50%) developed grade II hematologic toxicity. Regarding infections, pneumocystis pneumonia (PCP) occurred in Patient 7 after 56 days of Ru-D treatment and was successfully cured by trimethoprim-sulfamethoxazole. Patient 6 had a history of baseline bronchiectasis and chronic pulmonary infection with PA before receiving Ru-D. During treatment, this patient suffered aggravation of pulmonary infection and presented with cough, sputum, and inflammatory exudation changes on lung imaging and positive sputum culture for PA, while the body temperature remained within normal limits. She was treated with cefoperazone-sulbactam against PA but had poor control of the infection, developed massive hemoptysis on Day 19, and died in 48 hours. For other patients, no unusual infections were observed. Secondary HLH in adults is a major clinical challenge due to its rapid progression and high mortality. The current first-line treatment strategies are the HLH-94 and HLH-2004 regimens, the ORR was approximately 70%. There were 8 patients enrolled in our study, whose ORR was 87.5%, which is higher than the patients treated with the HLH-94/HLH-2004 regimen. The survival of adult patients with HLH is poor, in a large, multicenter, retrospective study, the median OS in patients with malignancy-associated HLH was 2.8 months and for those with non-malignancy-associated HLH was 10.7 months.3 We also have retrospectively analyzed 205 patients seen between January 2011 and December 2015 in our hospital. The median OS was only 1.8 months, and most of these patients received HLH-94 as initial treatment.6 In this study, the median OS was 4.7 months in patients with LAHS, and all the patients with non-LAHS are now alive with a CR status for more than one year. In contrast to the above studies, this study demonstrated better short-term survival in both malignancy-associated HLH and non-malignancy-associated HLH patients. In our study, Ru-D regimen shows that it is an efficient and safe initial treatment for patients with LAHS, the rapid control of cytokine-driven inflammation gives these patients opportunity to confirm the diagnosis of lymphoma and bridge to chemotherapy. Although Ru-D regimen may improve short-term survival in LAHS patients, their long-term survival remains poor. More effective anti-lymphoma strategies may be the fundamental way to improve the prognosis of these patients. Overall, the Ru-P regimen was well tolerated in this study. Regarding hematologic toxicity, only 1 patient (25%) developed grade III hematologic toxicity. The peripheral blood cell counts of patients who responded gradually improved during Ru-D treatment. However, it should be noted that during Ru-D treatment, we found 2 cases of grade III or higher infection-related AE. Therefore, during Ru-D treatment, we should be aware of the aggravation of the original infection and new opportunistic infections. More experience is needed to assess the need for prophylactic anti-infective therapy in these patients. In summary, this study was a preliminary attempt at giving the Ru-D regimen to newly diagnosed adult HLH patients. Although the sample size was small and the follow-up time was relatively short. Given the rarity and high short-term mortality of adult HLH, the results of this study have some relevance indeed. Ru-D showed a high ORR and good safety and has the potential to become a first-line treatment for HLH in adults. AUTHOR CONTRIBUTIONS De Zhou, Honghu Zhu, Jie Jin, Xiujin Ye, and Xianbo Huang designed the study; De Zhou, Xianbo Huang, and Mixue Xie analyzed the results; De Zhou and Xianbo Huang wrote the paper; De Zhou, Xiu jin Ye, Xianbo Huang, and Xueying Li performed the research; Xin Huang, Xiudi Yang, Li LI, Lixia Zhu, Jingjing Zhu, Xiaolong Zheng, Jianai Sun, Shuqi Zhao, Wenjuan Yu, Wanzhuo Xie, and Hongyan Tong collected the data and reviewed the paper. De Zhou, Xiujin Ye, and Xianbo Huang obtained funding. Honghu Zhu and Jie Jin provided administrative support. All authors read and approved the final manuscript. ACKNOWLEDGMENTS The authors thank the patients and their families, and medical staff who participated in this study. This work was supported by grants from Zhejiang Provincial Natural Science Foundation of China (No. LGF22H160040 and LZ22H080002), and Natural Science Foundation of China (No. 81900152). The funder of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. CONFLICT OF INTEREST STATEMENT The authors declare no conflict of interest. Open Research DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request. REFERENCES 1Schram AM, Comstock P, Campo M, et al. Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. Br J Haematol. 2016; 172: 412- 419. 2Henter JI, Samuelsson-Horne A, Arico M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002; 100: 2367- 2373. 3Ahmed A, Merrill SA, Alsawah F, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-Centre, pilot trial. Lancet Haematol. 2019; 6(12):e630-e637. 4Meyer LK, Verbist KC, Albeituni S, et al. JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation. Blood. 2020; 136(6): 657- 668. 5Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary Hemophagocytic Lymphohistiocytosis. N Engl J Med. 2020; 382(19): 1811- 1822. 6Zhou M, Li L, Zhang Q, et al. Clinical features and outcomes in secondary adult hemophagocytic lymphohistiocytosis. Int J Med. 2018; 111: 23- 31. Volume98, Issue5May 2023Pages E106-E109 ReferencesRelatedInformation

Abstract:Clinical and Translational MedicineVolume 11, Issue 11 e571 LETTER TO EDITOROpen Access The concentrated antibody from convalescent plasma balanced the dysfunctional immune responses in patients with critical COVID-19 Mingfeng Liao, Mingfeng Liao National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, ChinaSearch for more papers by this authorXuejiao Liao, Xuejiao Liao National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, ChinaSearch for more papers by this authorJing Yuan, Jing Yuan Department for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, ChinaSearch for more papers by this authorBing Zhou, Bing Zhou National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, ChinaSearch for more papers by this authorYang Liu, Yang Liu National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, ChinaSearch for more papers by this authorXiao Jiang, Xiao Jiang Department for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, ChinaSearch for more papers by this authorZhan Zhang, Zhan Zhang Guangdong Province Research & Development Centre of Protein (Peptide) Separation Engineering Technology, Shenzhen, ChinaSearch for more papers by this authorCaiping Guo, Caiping Guo Guangdong Province Research & Development Centre of Protein (Peptide) Separation Engineering Technology, Shenzhen, ChinaSearch for more papers by this authorYunjia Zhang, Yunjia Zhang Guangdong Province Research & Development Centre of Protein (Peptide) Separation Engineering Technology, Shenzhen, ChinaSearch for more papers by this authorShuye Zhang, Shuye Zhang Shanghai Public Health Clinical Center, Fudan University, Shanghai, ChinaSearch for more papers by this authorLei Liu, Corresponding Author Lei Liu [email protected] National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China Shenzhen Research Center for Communicable Disease Diagnosis and Treatment of Chinese Academy of Medical Science, Shenzhen, Guangdong Province, China Correspondence Shuye Zhang, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. Lei Liu, Department for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province 518100, China. Email: [email protected] Zheng Zhang, National Clinical Research Center for Infectious Disease, Institute of Hepatology, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province 518100, China. Email: [email protected]Search for more papers by this authorZheng Zhang, Corresponding Author Zheng Zhang [email protected] orcid.org/0000-0002-3544-1389 National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China Shenzhen Research Center for Communicable Disease Diagnosis and Treatment of Chinese Academy of Medical Science, Shenzhen, Guangdong Province, China Shenzhen Bay Laboratory, Shenzhen, Guangdong Province, China Correspondence Shuye Zhang, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. Lei Liu, Department for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province 518100, China. Email: [email protected] Zheng Zhang, National Clinical Research Center for Infectious Disease, Institute of Hepatology, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province 518100, China. Email: [email protected]Search for more papers by this author Mingfeng Liao, Mingfeng Liao National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, ChinaSearch for more papers by this authorXuejiao Liao, Xuejiao Liao National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, ChinaSearch for more papers by this authorJing Yuan, Jing Yuan Department for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, ChinaSearch for more papers by this authorBing Zhou, Bing Zhou National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, ChinaSearch for more papers by this authorYang Liu, Yang Liu National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, ChinaSearch for more papers by this authorXiao Jiang, Xiao Jiang Department for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, ChinaSearch for more papers by this authorZhan Zhang, Zhan Zhang Guangdong Province Research & Development Centre of Protein (Peptide) Separation Engineering Technology, Shenzhen, ChinaSearch for more papers by this authorCaiping Guo, Caiping Guo Guangdong Province Research & Development Centre of Protein (Peptide) Separation Engineering Technology, Shenzhen, ChinaSearch for more papers by this authorYunjia Zhang, Yunjia Zhang Guangdong Province Research & Development Centre of Protein (Peptide) Separation Engineering Technology, Shenzhen, ChinaSearch for more papers by this authorShuye Zhang, Shuye Zhang Shanghai Public Health Clinical Center, Fudan University, Shanghai, ChinaSearch for more papers by this authorLei Liu, Corresponding Author Lei Liu [email protected] National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China Shenzhen Research Center for Communicable Disease Diagnosis and Treatment of Chinese Academy of Medical Science, Shenzhen, Guangdong Province, China Correspondence Shuye Zhang, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. Lei Liu, Department for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province 518100, China. Email: [email protected] Zheng Zhang, National Clinical Research Center for Infectious Disease, Institute of Hepatology, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province 518100, China. Email: [email protected]Search for more papers by this authorZheng Zhang, Corresponding Author Zheng Zhang [email protected] orcid.org/0000-0002-3544-1389 National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China Shenzhen Research Center for Communicable Disease Diagnosis and Treatment of Chinese Academy of Medical Science, Shenzhen, Guangdong Province, China Shenzhen Bay Laboratory, Shenzhen, Guangdong Province, China Correspondence Shuye Zhang, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. Lei Liu, Department for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province 518100, China. Email: [email protected] Zheng Zhang, National Clinical Research Center for Infectious Disease, Institute of Hepatology, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province 518100, China. Email: [email protected]Search for more papers by this author First published: 04 November 2021 https://doi.org/10.1002/ctm2.571 Mingfeng Liao, Xuejiao Liao, Jing Yuan, and Bing Zhou contributed equally to this work. AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Dear Editor, This study found that the concentrated antibody therapy was able to clear residual virus reservoirs, increase neutralizing antibody levels and the overall immune response by enhancing peripheral lymphocyte counts and neutrophil–lymphocyte ratio when given during the early phase of SARS-CoV-2 infection. To the Editor: Due to the absence of specific and effective treatment for coronavirus disease-2019 (COVID-19), antibody therapy is of great interest.1 With the strong specificity, the antibody therapy is suitable for emergency use. While therapeutic antibodies and convalescent plasma were promising and facilitating patient recovery,2-5 the clinical benefit and immunological effects of therapies using plasma and concentrated antibody from convalescent donors remain uncertain. Here, we conducted a non-randomized clinical trial using concentrated antibodies to treat critically ill COVID-19 patients. Thirteen COVID-19 patients were enrolled in this study at the Shenzhen Third People's Hospital from late January to August, 2020. The demographic data of the patients were shown in Table 1. Seven patients (S1–S7) received concentrated antibody and (or) convalescent plasma treatment as the intervention group, and the other six patients (S8–S13) without no plasma or antibody therapy were followed as the control group. Health history of the both groups showed a very slight and nonsignificant difference (Table S1). Concentrated antibodies were derived from the plasma of fourteen convalescent COVID-19 donors (Table 2, Supplemental Methods and Materials). TABLE 1. Clinical characteristics of 13 COVID-19 patients at Shenzhen third people's hospital, January to August 2020 S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 S13 Severity Critical Critical Critical Critical Critical Critical Critical Critical Critical Critical Critical Critical Critical Age (years) 46 73 69 64 69 70 29 72 36 69 57 66 63 Gender Male Male Male Female Male Female Male Male Male Male Female Male Female Wuhan traveling Yes Yes Yes No No No No Yes No Yes No No No Symptom onset date/first symptom 2020-1-21 Fever, cough 2020-1-20 Fever 2020-1-21 Fever, dizzy 2020-1-29 Fever, cough 2020-1-31 Fever 2020-3-4 Fever 2020-4-24 Fever 2020-1-4 Fever, cough 2020-1-19 Fever, cough 2020-1-11 Fever, cough, pharyngeal pain 2020-1-21 Dizzy, cough, pharyngeal pain 2020-1-20 Fever, weak 2020-1-12 Fever, cough Hospitalization date 2020-1-22 2020-1-22 2020-1-24 2020-2-7 2020-2-3 2020-3-6 2020-4-27 2020-1-20 2020-1-28 2020-1-20 2020-1-23 2020-1-24 2020-1-27 Convalescent Plasma Transfusion (date) ND Yes 2020-2-13; 2020-2-23 ND ND Yes 2020-2-15 ND Yes 2020-5-3 ND ND ND ND ND ND Neutralizing antibody Transfusion (date) Yes 2020-2-2 Yes 2020-2-2; 2020-3-7 Yes 2020-2-19 Yes 2020-2-19 Yes 2020-2-19 2020-3-7 Yes 2020-3-12 Yes 2020-5-1 ND ND ND ND ND ND Outcome/date Cured 2020-3-8 Death 2020-7-23 Death 2020-2-26 Cured 2020-3-11 Death 2020-10-10 Cured 2020-4-1 Cured 2020-5-21 Cured 2020-2-23 Cured 2020-2-26 Cured 2020-2-8 Cured 2020-3-7 Cured 2020-3-6 Cured 2020-3-6 Chronic basic disease None HTN Diabetes SP HTN Coronary heart disease Diabetes HTN None HTN None None None Medication history None None None None None None None None None None None None None SARS-CoV-2 RT-qPCR (Ct value, Before or Transfusion Day)/sample +(30.97) BALF 2020-2-2 +(27.67) Throat swab 2020-2-2 +(36.2) Sputum 2020-2-19 +(37.8) Nasal swab 2020-02-19 +(27.7) Sputum 2020-2-19 +(26.3) Sputum 2020-3-12 +(40) Nasal swab 2020-4-28 +(21.6) Sputum 2020-1-28 +(24.8) Nasal swab 2020-2-10 +(23) Sputum 2020-1-20 +(22.5) Throat swab 2020-1-24 +(26.5) Throat swab 2020-1-24 +(23.8) Nasal swab 2020-1-30 Flu A/B –/– –/– –/– –/– –/– –/– –/– –/– –/– –/– –/– –/– –/– RSV virus – – – – – – – – – – – – – Adenovirus – – – – – – – – – – – – – Interferon atomization 2020-1-22 2020-1-22 2020-1-24 2020-2-7 2020-2-4 2020-3-6 2020-4-27 2020-1-20 2020-1-28 2020-1-20 2020-1-23 No No Ribavirin 2020-1-23 2020-1-22 NO 2020-2-12 2020-2-11 No No 2020-1-20 No 2020-1-20 No No No Methylprednisolone Yes Yes Yes Yes Yes No Yes Yes Yes No Yes Yes Yes SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; RT-PCR, reverse transcription polymerase chain reaction; Ct, cycle threshold; BALF, bronchoalveolar lavage fluid; HTN, hypertension; SP, schizophrenic; Flu, influenza. TABLE 2. Characteristics and antibody titer of convalescent plasma donors Number Gender Age Disease severity Interval between symptom onset and discharge Interval between discharge and plasma donation Donated plasma volume (ml) Blood type For antibody therapy For convalescent plasma RBD-specific IgG ELISA titer RBD-specific IgM ELISA titer Neutralizing antibody titer Infectious pathogen 1 Male 36 Moderate 17 4 500 B+ Yes – 200 1800 NT – 2 Male 35 Moderate 15 8 500 O+ Yes – 600 600 NT – 3 Male 51 Moderate 18 11 300 O+ Yes – 278 612 670 NT – 4 Female 52 Moderate 18 9 500 O+ Yes – NT NT NT – 5 Male 42 Moderate 16 14 500 O+ Yes – 259 418 171 002 NT – 6 Male 51 Moderate 24 5 500 A+ Yes – 16 200 48 600 NT – 7 Male 19 Moderate 22 5 500 A+ Yes – 16 200 48 600 NT – 8 Female 49 Moderate 20 17 480 A+ Yes – 112 720 6053 NT – 9 Female 50 Moderate 19 16 400 B+ Yes – 671 429 102 565 NT – 10 Male 54 Moderate 16 16 400 B+ Yes – 16 200 16 200 NT – 11 Male 47 Severe 34 23 400 B+ Yes – 437 400 437 400 NT – 12 Female 36 Moderate 22 23 400 O+ Yes – 48 600 16 200 NT – 13 Female 47 Moderate 27 21 400 0+ Yes – 16 200 16 200 NT – 14 Male 28 Moderate 15 22 400 AB+ Yes – 16 200 48 600 NT – RBD, receptor-binding domain; IgG, immunoglobulin G; ELISA, enzyme-linked immunosorbent assay. We first investigated the effects of concentrated antibody on viral clearance. The virus Ct values began to increase after two days of concentrated antibody treatment and were then remained undetectable within 10 days posttransfusion for 6 treated patients (Figure 1A). In contrast, SARS-COV-2 in the control group was cleared at 14–48 days postsymptom onset (Figure S1A). The virus titer decreased significantly after concentrated antibody treatment (P = 0.00204) (Figure S1B). FIGURE 1Open in figure viewerPowerPoint Monitoring SARS-CoV-2 viral loads among the enrolled COVID-19 patients. (A) The serial viral Ct values in concentrated antibody therapy group; (B) Representative Viral-Track analysis data. For each potential viral genome, represented by a dot, the entropy of the sequence (how repetitive are the mapped sequences) and the percentage of the segment that is mapped are plotted. Green dots correspond to viral segments that have passed quality control. Viral genomes with more than 50 mapped reads are plotted. (C) Viral-Track analysis of SARS-CoV-2 reads in BALF scRNA-seq data collected before and after the antibody treatment. D0 is the symptom onset date in (A). The square cross indicates the reception of the convalescent plasma transfusion and the diamond plus indicates the reception of concentrated neutralizing antibody treatment as indicated. Tombstone indicates fatal patients (S2, S3, S5). Pedestrian indicates cured patients (S1, S4, S6, S7) We and others have detected residual virus in lung tissues even though continuous SARS-CoV-2 negativity in the nasal, throat swabs and sputum.6, 7 It was proposed that the ongoing viral activity may contribute to COVID-19 severity. Thus, we questioned whether the concentrated antibody therapy could clear the virus reservoir. We applied Viral-Track8 mining the scRNA-seq data of Bronchoalveolar lavage fluid (BALF) samples from two patients before and after the antibody treatment. Total numbers of viral reads mapped to the SARS-CoV-2 viral genome were 7, 460 for S1, and 178 for S2 before the antibody treatment, respectively (Figure 1C); in contrast, no viral read was detected in samples after the treatment. We further confirmed the SARS-CoV-2 as the only virus in the analyzed data with Viral-Track (Figure 1B). The viral reads were found to be enriched in the epithelial cells, plasma cells, macrophages and T cells (Figure S1C). The pathway analysis indicated an enhanced antiviral function of T cells after treatment (Figure S2). Previous studies have reported the decreased T cell counts in peripheral blood of COVID-19 patients; particularly, the decreased CD8 T cells were significantly correlated with disease severity.9 Here, we explore whether the antibody therapy affects cellular immunity. We found the concentrated antibody treatment significantly increased T cell counts in peripheral blood (Figure S3A–C). Importantly, the CD8/CD4 ratio in cured patients receiving concentrated antibody (S1, S4, S6, S7) was remained above 0.5 from 8–17 days after symptom onset, except for patient S6 whose CD8/CD4 ratio was always below 0.5 (Figure S3D; this value was the lower limitation of CD8/CD4 ratio in healthy Chinese adults). By contrast, among those patients with fatal outcomes (S2, S3, S5) even receiving concentrated antibody, the CD8/CD4 ratio decreased and reached the lowest point at 13–16 days postsymptoms onset (Figure S3E). In the control group, the CD8/CD4 ratio gradually decreased after disease onset, reaching the lowest point 14–24 days after symptom onset (Figure S3F, Extended Data 1). Neutrophil–lymphocyte ratio (NLR) was also correlated with COVID-19 severity and prognosis, and the NLR more than 11.75 is strongly associated with the higher mortality. In the current study, the NLR was remained below 11.75 in most of the cured patients (Figure S3G) although it fluctuated greatly at higher levels in the fatal patients (Figure S3H). In the control group, the NLR fluctuated until 14–28 days postdisease onset (Figure S3I). The right timing for antibody therapy is still unclear. We hypothesized that early treatment would favor the recipient to initialize robust antibody response by themselves. Patient S1, S5, S6, and S7 started therapy at 12, 8, 7, and 7 days after the symptoms onset, respectively. They showed increased neutralizing antibody titers along with the increased IgG, IgM, IgA, and total immmunoglobulin concentrations after the concentrated antibody treatment (Figure 2A, B). In contrast, patient S3 and S4 received the concentrated antibody therapy at 29 and 21 days after the symptoms onset, respectively. Little improvement in either neutralizing or total antibodies was observed by the treatment in the two patients (Figure 2A, B). Patient S2 received the treatment at 13 days after the symptom onset. The total immmunoglobulin and neutralizing antibody levels reach stable high level after the antibody transfusion (Figure 2B). These preliminary data indicated that the earlier Ab treatment possibly facilitated disease recovery from severe COVID-19. FIGURE 2Open in figure viewerPowerPoint Monitoring binding antibody and neutralizing antibody levels among the treated COVID-19 patients. The levels of neutralizing antibody and RBD-binding antibody (IgG, IgM, IgA, and total Ig) before and after concentrated antibody therapy in treated patients S1–S7. (A) Cured patients (S1, S4, S6, S7); (B) fatal patients (S2, S3, S5) We suspect that the antibody therapy may also affect proinflammatory responses because antibody-dependent cytokine release (ADCR). Plasma IL-6, procalcitonin, and C-reacting protein (CRP) were dynamically monitored. After antibody treatment, the IL-6 levels were increased rapidly in six of the seven patients (Figure S4A). Notably, IL-6 in patient S2 remained at a lower level for 30 days after the first antibody treatment, but showed a transient increase after the second antibody treatment then followed by decrease to low levels (Figure S4B). We also observed the similar changes of CRP, procalcitonin mirrored IL-6 patterns in patient S1 to S7 (Figure S4C–F). In summary, we found that concentrated antibody therapy may help clear viral reservoirs in infected lung tissues of critical COVID-19 patients, likely through antibody mediated effector functions. Although the transfused antibodies may cause a transient increase of the inflammatory cytokines, they contribute to the improvement of the overall immune homeostasis and could be used during the early phase of COVID-19. These findings provide novel evidences for ongoing monoclonal antibody therapy for COVID-19. ACKNOWLEDGMENTS The authors wish to thank the Cell Bank and clinical staff of the Shenzhen Third People's Hospital for biosamples and services provided in the study. FUNDING INFORMATION This study was supported by the National Science Fund for Distinguished Young Scholars (82025022), the Science and Technology Innovation Committee of Shenzhen Municipality (JSGG20200207155251653, JSGG20200807171401008, KQTD20200909113758004), and the Guangdong Basic Applied Basic Research Foundation (2020B111122002 and 2020B1111340035). CONFLICT OF INTEREST The authors declare that there is no conflict of interest. Supporting Information Filename Description ctm2571-sup-0001-SuppMat.docx46.7 KB Supporting Information ctm2571-sup-0002-FigureCaption.docx32.6 KB Supporting Information ctm2571-sup-0003-FigureS1.tif602.3 KB Supporting Information ctm2571-sup-0004-FigureS2.tif245.4 KB Supporting Information ctm2571-sup-0005-FigureS3.tif328.7 KB Supporting Information ctm2571-sup-0006-FigureS4.tif317.5 KB Supporting Information ctm2571-sup-0007-Table1.docx17.4 KB Supporting Information Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. REFERENCES 1Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021; 21: 382- 393. 2Libster R, Pérez Marc G, Wappner D, et al. early high-titer plasma therapy to prevent severe COVID-19 in older adults. N Engl J Med. 2021; 384: 610- 618. 3Joyner MJ, Senefeld JW, Klassen SA, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. medRxiv. 2020. 4Chen P, Nirula A, Heller B, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N Engl J Med. 2021. 5Marovich M, Mascola JR, Cohen MS. Monoclonal antibodies for prevention and treatment of COVID-19. JAMA. 2020; 324: 131- 132. 6Xu G, Liu Y, Liao M, et al. Persistent viral activity, cytokine storm, and lung fibrosis in a case of severe COVID-19. Clin Transl Med. 2020; 10:e224. 7Yao XH, He ZC, Li TY, et al. Pathological evidence for residual SARS-CoV-2 in pulmonary tissues of a ready-for-discharge patient. Cell Res. 2020; 30: 541- 543. 8Bost P, Giladi A, Liu Y, et al. Host-viral infection maps reveal signatures of severe COVID-19 patients. Cell. 2020; 181: 1475- 1488. e1412. 9Zhang Y, Mo P, Ma Z, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis. 2020; 221: 1762- 1769. Volume11, Issue11November 2021e571 FiguresReferencesRelatedInformation

Hemorrhagic Fever with Renal Syndrome: Treatment with Recombinant Interferon

Ruxolitinib Combined with Dexamethasone in Adult Patients with Newly Diagnosed Hemophagocytic Lymphohistiocytosis: A Single‐center Pilot Trial

The Study Design and Methodology of Antibiotic Duration in Hematological Patients with Pseudomonas Aeruginosa Bloodstream Infection.

The Concentrated Antibody from Convalescent Plasma Balanced the Dysfunctional Immune Responses in Patients with Critical COVID‐19

Treatment of a Patient with Severe Hemorrhagic Fever Accompanied by Infection with Methicillinresistant Staphylococcus Aureus, Acinetobacter Baumannii, Aspergillus and Mucor: a Case Report.

The Necessity of Studying Antibiotic Duration in Acute Leukemia Patients with Pseudomonas Aeruginosa Bloodstream Infection: A Response to Terada and Kanno

Clinical Characteristics and Current Treatment of Critically Ill Patients with COVID-19 Outside Wuhan, China: A Multicenter, Retrospective, Observational Study

Persistent Viral Activity, Cytokine Storm, and Lung Fibrosis in a Case of Severe COVID‐19

Evaluation of Plasma Exchange and Continuous Veno‐Venous Hemofiltration for the Treatment of Severe Avian Influenza <scp>A</scp> (<scp>H7N9</scp>): A Cohort Study

Tcrm_a_206930 911..919

Withdrawal: Prospective Randomized Comparison Between Upgraded “2C3L” Versus PVI Approach for Catheter Ablation of Persistent Atrial Fibrillation: PROMPT‐AF Trial Design

Resveratrol Inhibits the Replication of Severe Acute Respiratory Syndrome Coronavirus 2 (sars‐cov‐2) in Cultured Vero Cells

OEM China Water Storage Bladder Tanks OEM/ODM Quotes - Rongda

Expert Consensus on the Prevention and Treatment of Hemorrhagic Fever with Renal Syndrome

The Epidemic Characteristics and Changing Trend of Hemorrhagic Fever with Renal Syndrome in Hubei Province, China.

Hemorrhagic fever with renal syndrome caused by Hantaan virus infection in 4 pregnant Chinese women † Running title : Hantavirus infection in pregnancy

Mapping the Epidemic Changes and Risks of Hemorrhagic Fever with Renal Syndrome in Shaanxi Province, China, 2005–2016

Assessment of the Risk of Nosocomial 2009 H1N1 Influenza Infection among Obstetric Care Workers

Hemorrhagic Fever with Renal Syndrome Complicated by Acute Pancreatitis, High Intraocular Pressure, and Pulmonary Involvement: a Case Report

Mapping The Epidemic Changes And Risks Of Hemorrhagic Fever With Renal Syndrome In Shaanxi Province, China, 2005-2016 (Vol 8, 2018)

Epidemiological Analysis of Hemorrhagic Fever with Renal Syndrome in Xian City from 2005 to 2009